ArticleUltrasonics sonochemistry2026
Optimization of deep eutectic solvents-based ultrasonic-assisted three-phase partitioning extraction of polysaccharides from Pleurotus tuber-regium and its anti-ulcerative colitis activity.
Article in Ultrasonics sonochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Based on the various anti-inflammatory and antioxidant bioactivities of Pleurotus tuber-regium and its polysaccharides (PTPs), they represent promising candidates for complementary or alternative therapeutic strategies against Ulcerative Colitis (UC), but conventional extraction methods are often inefficient or environmentally unfriendly. This study presents a novel integrated deep eutectic solvents (DESs)-based ultrasonic-assisted three-phase partitioning (TPP) extraction technique of PTPs to solve the dual challenges of inefficient traditional extraction methods and the unexplored therapeutic potential of PTPs against UC. First, it establishes an optimized and sustainable extraction process, enhancing the yield and potential bioavailability of PTPs. Single-factor assays followed by Box-Behnken Design (BBD) were employed to optimize key parameters: DES-2 (choline chloride:1,6-hexanediol = 1:2, molar ratio), temperature 40℃, material-liquid ratio 1:33 mg/mL, ammonium sulphate mass fraction 15%, upper and lower phase (ammonium sulphate: DES-2) volume ratio 1:2, time 40 min, power 320 W. Structural characterization utilized UV spectrophotometer (UV-Vis) and Fourier transform infrared (FT-IR) spectrometer, high-performance gel permeation chromatography (HPGPC), and scanning electron microscopy (SEM). Monosaccharide composition was analyzed via PMP derivatization and HPLC. Second, it provides the first comprehensive preclinical evidence, using dextran sulfate sodium (DSS)-induced Drosophila colitis model, to systematically validate the anti-UC efficacy of the optimized PTPs extract. The findings bridge a critical gap, offering both an advanced extraction method for efficient utilization of PTPs and a pharmacological foundation for developing PTPs as a promising nutraceutical or botanical drug candidate for inflammatory bowel disease management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.